meglumine antimoniate has been researched along with Disease Models, Animal in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguiar, MG; Araújo, RS; Barros, ALB; da Conceição, EC; de Oliveira, LG; Fernandes, AP; Fernandes, CP; Ferreira, LAM; Kawakami, MYM; Oliveira, AEMFM; Queiroz-Junior, CM; Ricotta, TQN; Zamora, LO | 1 |
| Anversa, L; Batista, LR; Cuba, MB; Dias da Silva, VJ; Martins, TY; Nogueira Nascentes, GA; Ramirez, LE; Richini Pereira, VB; Ruiz, LDS; Salles Tiburcio, MG | 1 |
| Cedeño, DL; Fernandez, M; Jones, MA; Murillo, J; Ocampo-Cardona, R; Ríos-Vásquez, LA; Robledo, SM; Velez, ID | 1 |
| Borborema, SET; de Andrade Junior, HF; do Nascimento, N; Osso Junior, JA; Tempone, AG | 1 |
| Almeida, TC; da Silva, ATP; da Silva, GN; Perasoli, FB; Rezende, SA; Silva, DF; Silva, SC | 1 |
| de Arias, AR; Lima, AP; Maldonado, M; Pandolfi, E; Schinini, A; Serna, ME; Torres, S | 1 |
| Aguiar, MG; de Morais-Teixeira, E; Ferreira, LA; Rabello, A; Soares de Souza Lima, B | 1 |
| Aït-Oudhia, K; Benbetka, S; Benikhlef, R; Eddaikra, N; Harrat, Z; Kherachi Djenad, I; Moulti-Mati, F; Oury, B; Sereno, D | 1 |
| Andrade, MS; Corrêa-Júnior, JD; Demicheli, C; Fernandes, FR; Ferreira, LA; Frézard, F; Lanza, JS; Magalhães-Paniago, R; Melo, MN; Vilela, JM | 1 |
| Corpas-López, V; Díaz-Sáez, V; Gijón-Robles, P; López-Viota, J; López-Viota, M; Martín-Sánchez, J; Merino-Espinosa, G; Morillas-Mancilla, MJ; Morillas-Márquez, F; Navarro Moll, MC | 1 |
| Galindo-Sevilla, N; Mancilla-Ramirez, J; Martinez-Rojano, H; Quiñonez-Diaz, L | 1 |
| Delgado, G; Granados, D; Mariño, A; Plaza, D; Sánchez, Y | 1 |
| Barati, M; Fasihi Harandi, M; Hakimi Parizi, M; Khamesipour, A; Nakhaee, N; Nosratabadi, J; Sharifi, I; Shokri, A | 1 |
| Amaral, V; Campos, MC; Canto-Cavalheiro, MM; Charret, KS; Dos Reis, C; Echevarria, A; Leon, LL; Rodrigues, RF | 1 |
| Forouzannia, SK; Pourrajab, F; Tabatabaee, SA | 1 |
| Gómez, A; Henao, HH; Osorio, Y; Saravia, NG; Travi, B | 1 |
| Abdi, K; Darabi, M; Ghareghozloo, B; Kariminia, A; Solgi, G | 1 |
| Grimaldi, GJ; Oliveira-Neto, MP; Porrozzi, R; Teva, A | 1 |
| Steck, EA | 1 |
| Derouin, F; Gangneux, JP; Garin, YJ; Sulahian, A | 2 |
| Astier, A; Bories, C; Deniau, M; Durand, R; Fusai, T; Houin, R; Paul, M; Rivollet, D | 1 |
| Anacleto, C; Andrade, AF; Ferreira, AV; Gazola, KC; Michalick, MS; Moreira, ES | 1 |
| Bevilaqua, CM; Costa, DC; Prata, JR; Rocha, MF; Sidrim, JJ; Simões-Mattos, L; Teixeira, MJ | 1 |
| Barrios, AA; Cavé, A; Fournet, A; Hocquemiller, R; Muñoz, V | 1 |
1 review(s) available for meglumine antimoniate and Disease Models, Animal
| Article | Year |
|---|---|
The chemotherapy of protozoal infections: whither?
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Models, Animal; Glycolipids; Humans; Leishmaniasis; Leishmaniasis, Visceral; Liposomes; Lysosomes; Malaria; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Primaquine; Protozoan Infections; Trypanosomiasis | 1981 |
24 other study(ies) available for meglumine antimoniate and Disease Models, Animal
| Article | Year |
|---|---|
Efficacy of nanoemulsion with Pterodon emarginatus Vogel oleoresin for topical treatment of cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Cytokines; Disease Models, Animal; Drug Compounding; Drug Therapy, Combination; Emulsions; Fabaceae; Female; Host-Parasite Interactions; Leishmania mexicana; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mesocricetus; Mice, Inbred BALB C; Nanoparticles; Parasite Load; Plant Extracts; Skin; Trypanocidal Agents | 2021 |
Amiodarone and itraconazole improve the activity of pentavalent antimonial in the treatment of experimental cutaneous leishmaniasis.
Topics: Amiodarone; Animals; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Hindlimb; Histocytochemistry; Itraconazole; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Skin; Treatment Outcome | 2017 |
In vivo studies of the effectiveness of novel N-halomethylated and non-halomethylated quaternary ammonium salts in the topical treatment of cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Body Weight; Cricetinae; Disease Models, Animal; Female; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Quaternary Ammonium Compounds; Salts; Skin; Toxicity Tests | 2018 |
Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Death; Disease Models, Animal; Drug Compounding; Drug Liberation; Female; Leishmaniasis, Visceral; Liposomes; Meglumine; Meglumine Antimoniate; Mice, Inbred BALB C; Organometallic Compounds; Phosphatidylserines; Tissue Distribution | 2018 |
Behavior of two Leishmania infantum strains-evaluation of susceptibility to antimonials and expression of microRNAs in experimentally infected J774 macrophages and in BALB/c mice.
Topics: Animals; Antimony Potassium Tartrate; Antiparasitic Agents; Bone Marrow; Disease Models, Animal; Dogs; Female; Gene Expression Profiling; Humans; Leishmania infantum; Leishmaniasis, Visceral; Liver; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; MicroRNAs; Organometallic Compounds; Parasite Load; Spleen | 2018 |
Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum.
Topics: Animals; Anthelmintics; Bibenzyls; Disease Models, Animal; Leishmania infantum; Leishmaniasis, Visceral; Liver; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Phenols; Spleen | 2015 |
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Schedules; Disease Models, Animal; Drug Therapy, Combination; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome | 2015 |
Development of a Murine Infection Model with Leishmania killicki, Responsible for Cutaneous Leishmaniosis in Algeria: Application in Pharmacology.
Topics: Algeria; Animals; Disease Models, Animal; Humans; Leishmania infantum; Leishmania major; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Organometallic Compounds; Spleen | 2016 |
Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Drug Carriers; Female; Hydrophobic and Hydrophilic Interactions; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice, Inbred BALB C; Microscopy, Atomic Force; Nanoparticles; Organometallic Compounds; Scattering, Small Angle; Solvents; Treatment Outcome; X-Ray Diffraction | 2016 |
Topical Treatment of Leishmania tropica Infection Using (-)-α-Bisabolol Ointment in a Hamster Model: Effectiveness and Safety Assessment.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cricetinae; Cytochrome P-450 CYP2D6 Inhibitors; Disease Models, Animal; Injections, Intralesional; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Molecular Structure; Monocyclic Sesquiterpenes; Organometallic Compounds; Sesquiterpenes; Skin; Stereoisomerism | 2016 |
Activity of hydroxyurea against Leishmania mexicana.
Topics: Animals; Antiprotozoal Agents; Cell Cycle; Disease Models, Animal; Humans; Hydroxyurea; In Vitro Techniques; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitic Sensitivity Tests | 2008 |
An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Immunomodulation; In Vitro Techniques; Injections, Intramuscular; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Organometallic Compounds; Species Specificity; Toxicity Tests | 2011 |
The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Calcium Channel Blockers; Colorimetry; Disease Models, Animal; Drug Synergism; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitic Sensitivity Tests; Verapamil | 2012 |
The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania infantum; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Thiadiazoles; Treatment Outcome | 2012 |
Novel immunomodulatory function of 1,3,4-thiadiazole derivatives with leishmanicidal activity.
Topics: Animals; Antiprotozoal Agents; Cytokines; Disease Models, Animal; Histocytochemistry; Immunologic Factors; Injections, Intraperitoneal; Leishmaniasis; Liver; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Skin; Spleen; Thiadiazoles; Treatment Outcome | 2012 |
[Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2004 |
Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Female; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Interleukin-12; Leishmania major; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Thalidomide; Time Factors | 2006 |
Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Immunity, Cellular; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macaca mulatta; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2005 |
Activity of IFN-gamma in experimental Leishmania infantum murine visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Administration Schedule; Female; Interferon-gamma; Leishmania infantum; Leishmaniasis, Visceral; Liver; Lung; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Recombinant Proteins; Spleen | 1997 |
Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model.
Topics: Animals; Antimony; Antiprotozoal Agents; Colloids; Disease Models, Animal; Drug Carriers; Female; Leishmania major; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Microspheres; Organometallic Compounds; Pentamidine; Polymethacrylic Acids; Random Allocation | 1994 |
Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Paromomycin; Spleen | 1997 |
Cell surface carbohydrates and in vivo infectivity of glucantime-sensitive and resistant Leishmania (Viannia) guyjanensis cell lines.
Topics: Animals; Antimony; Antiprotozoal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cricetinae; Disease Models, Animal; Drug Resistance; Glycosphingolipids; Lectins; Leishmania guyanensis; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Time Factors | 2001 |
Evaluation of terbinafine treatment in Leishmania chagasi-infected hamsters (Mesocricetus auratus).
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leishmania; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Naphthalenes; Organ Size; Organometallic Compounds; Random Allocation; Spleen; Terbinafine; Treatment Outcome; Trypanocidal Agents; Zoonoses | 2002 |
Effect of natural naphthoquinones in BALB/c mice infected with Leishmania amazonensis and L. venezuelensis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Naphthoquinones; Organometallic Compounds; Plant Extracts | 1992 |